Table 2.
Proportion of eyes with >30% or ≥30% central ECL from preoperative
| Parameter | Time | ||
| 3 mo | 24 mo | 60 mo | |
| iStent inject + phaco (% eyes with > 30% ECL) | 11.2 (19/170) | 9.4 (16/171) | 9.4 (16/170) |
| iStent inject + phaco (% eyes with ≥ 30% ECL)a | 11.2 (19/170) | 9.4 (16/171) | 9.4 (16/170) |
| Phaco control | 14.3 (7/49) | 4.3 (2/47) | 6.3 (3/48) |
| P value | .55 | .37 FE | .77 FE |
| Diff % (95% CI) (treatment − control) | −3.1 (−14.0, 7.8) | 5.1 (−2.1, 12.3) | 3.2 (−5.0, 11.3) |
| Hydrus Microstent + phaco | 17.3 (61/352) | 13.6 (47/346) | 20.8 (62/298) |
| Phaco control | 9.4 (17/181) | 7.2 (12/167) | 10.6 (14/132) |
| P value | .01* | .03* | .01* |
| Diff % (95% CI) (treatment − control) | 7.9 (2.1, 13.7) | 6.4 (1.1, 11.7) | 10.2 (3.2, 17.2) |
| CyPass Micro-Stent + phaco | 9.6 (20/209) | 8.5 (18/212) | 27.2 (44/162) |
| Phaco control | 6.2 (4/65) | 3.0 (2/67) | 10.0 (4/40) |
| P value | .39 | .18 FE | .02* |
| Diff % (95% CI) (treatment − control) | 3.4 (−3.7, 10.5) | 5.5 (0.0, 11.0) | 17.2 (5.6, 28.7) |
ECL = endothelial cell loss; FE = Fisher exact test; phaco = phacoemulsification
Values are listed as % (n/N). Calculations of CyPass ECL >30% 2-sided P value are from FE, assuming normal data distribution and correlation of data over time. Bonferroni correction was not performed due to the positive correlation of the measures on the same eyes over time, where Bonferroni is known to be overly conservative. By contrast, the P values reported in Table 3 of the 5-year CyPass paper used a Bonferonni correction.
*
Statistically significant